ATE401328T1 - Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren - Google Patents
Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitorenInfo
- Publication number
- ATE401328T1 ATE401328T1 AT04751862T AT04751862T ATE401328T1 AT E401328 T1 ATE401328 T1 AT E401328T1 AT 04751862 T AT04751862 T AT 04751862T AT 04751862 T AT04751862 T AT 04751862T AT E401328 T1 ATE401328 T1 AT E401328T1
- Authority
- AT
- Austria
- Prior art keywords
- secretasis
- arylsulfonylpiperidines
- bridged
- gamma
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47014603P | 2003-05-13 | 2003-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401328T1 true ATE401328T1 (de) | 2008-08-15 |
Family
ID=33452372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04751862T ATE401328T1 (de) | 2003-05-13 | 2004-05-11 | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7368457B2 (de) |
| EP (1) | EP1641801B9 (de) |
| JP (1) | JP2007501859A (de) |
| CN (1) | CN1820010A (de) |
| AR (1) | AR044294A1 (de) |
| AT (1) | ATE401328T1 (de) |
| CA (1) | CA2525124A1 (de) |
| CL (1) | CL2004001011A1 (de) |
| DE (1) | DE602004015110D1 (de) |
| ES (1) | ES2308206T3 (de) |
| MX (1) | MXPA05012268A (de) |
| PE (1) | PE20050555A1 (de) |
| TW (1) | TW200510405A (de) |
| WO (1) | WO2004101562A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2006004880A2 (en) * | 2004-06-30 | 2006-01-12 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| CA2618087A1 (en) * | 2005-08-19 | 2007-03-01 | Elan Pharmaceuticals, Inc. | Bridged n-bicyclic sulfonamido inhibitors of gamma secretase |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| AR076936A1 (es) * | 2009-06-02 | 2011-07-20 | Vitae Pharmaceuticals Inc | Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1 |
| NZ598685A (en) | 2009-09-11 | 2013-05-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| ES2797123T3 (es) | 2011-12-21 | 2020-12-01 | Novira Therapeutics Inc | Agentes antivirales para la hepatitis B |
| CN104902885A (zh) | 2012-08-28 | 2015-09-09 | 爱尔兰詹森科学公司 | 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途 |
| PL2961732T3 (pl) | 2013-02-28 | 2017-09-29 | Janssen Sciences Ireland Uc | Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| EP3357906B1 (de) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamidesubstituierte pyrrolamidderivate und verwendung davon als medikamente zur behandlung von hepatitis b |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US20150216938A1 (en) | 2014-02-05 | 2015-08-06 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| HK1225389A1 (zh) | 2014-02-06 | 2017-09-08 | Janssen Sciences Ireland Uc | 氨磺酰基吡咯酰胺衍生物及其作为药物用於治疗乙型肝炎的用途 |
| WO2015131773A1 (zh) * | 2014-03-06 | 2015-09-11 | 上海海雁医药科技有限公司 | 作为食欲素受体拮抗剂的哌啶衍生物 |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| EP3356328A1 (de) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Kristalline formen eines hepatitis-b-viruzids |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
| MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| EP3966205A1 (de) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Company | In der behandlung einer hbv-infektion oder von hbv-induzierten erkrankungen nützliche amidderivate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04247081A (ja) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5員複素環酸アミド類 |
| HUP0201020A3 (en) | 1999-02-26 | 2003-04-28 | Bristol Myers Squibb Co | Novel sulfonamide compounds and uses thereof |
| WO2002076440A2 (en) * | 2001-03-23 | 2002-10-03 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
-
2004
- 2004-05-11 PE PE2004000484A patent/PE20050555A1/es not_active Application Discontinuation
- 2004-05-11 EP EP04751862A patent/EP1641801B9/de not_active Expired - Lifetime
- 2004-05-11 DE DE602004015110T patent/DE602004015110D1/de not_active Expired - Lifetime
- 2004-05-11 CA CA002525124A patent/CA2525124A1/en not_active Abandoned
- 2004-05-11 CN CNA200480019637XA patent/CN1820010A/zh active Pending
- 2004-05-11 JP JP2006532943A patent/JP2007501859A/ja active Pending
- 2004-05-11 TW TW093113229A patent/TW200510405A/zh unknown
- 2004-05-11 MX MXPA05012268A patent/MXPA05012268A/es not_active Application Discontinuation
- 2004-05-11 WO PCT/US2004/014671 patent/WO2004101562A2/en not_active Ceased
- 2004-05-11 ES ES04751862T patent/ES2308206T3/es not_active Expired - Lifetime
- 2004-05-11 AR ARP040101597A patent/AR044294A1/es not_active Application Discontinuation
- 2004-05-11 US US10/842,783 patent/US7368457B2/en not_active Expired - Fee Related
- 2004-05-11 CL CL200401011A patent/CL2004001011A1/es unknown
- 2004-05-11 AT AT04751862T patent/ATE401328T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004101562A3 (en) | 2005-02-10 |
| US20040229902A1 (en) | 2004-11-18 |
| EP1641801B9 (de) | 2009-02-25 |
| MXPA05012268A (es) | 2006-02-10 |
| ES2308206T3 (es) | 2008-12-01 |
| EP1641801A2 (de) | 2006-04-05 |
| US7368457B2 (en) | 2008-05-06 |
| TW200510405A (en) | 2005-03-16 |
| JP2007501859A (ja) | 2007-02-01 |
| AR044294A1 (es) | 2005-09-07 |
| WO2004101562A2 (en) | 2004-11-25 |
| CA2525124A1 (en) | 2004-11-25 |
| DE602004015110D1 (de) | 2008-08-28 |
| PE20050555A1 (es) | 2005-07-19 |
| CN1820010A (zh) | 2006-08-16 |
| CL2004001011A1 (es) | 2005-03-18 |
| EP1641801B1 (de) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401328T1 (de) | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren | |
| ATE402934T1 (de) | Malonamidderivate als gamma-secretaseinhibitoren | |
| ATE437876T1 (de) | Hexahydropyridoisochinoline als dpp-iv- inhibitoren | |
| ATE478868T1 (de) | Pyrrolodihydroisochinoline als pde10- inhibitoren | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| ATE426599T1 (de) | Thiazolylpiperidin derivate als mtp inhibitoren | |
| ATE525377T1 (de) | Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| DK1605897T3 (da) | Polyethelen-glycol-link-glp-1-forbindelser | |
| ATE443054T1 (de) | Cyano-pyrrolidine als dpp-iv inhibitoren | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| DE602004008303D1 (de) | Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 | |
| DE602004012154D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren | |
| IS8320A (is) | N-staðgengnir pýrasólýl-amidýl-bensimidasólýl | |
| ATE411306T1 (de) | Biarylsulfonamide als mmp-inhibitoren | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| ATE538787T1 (de) | Benzimidazol-derivative als raf-kinase-hemmer | |
| ATE461926T1 (de) | Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer | |
| DE502004006055D1 (de) | 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren | |
| ATE402700T1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
| ATE462692T1 (de) | 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |